Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP) (original) (raw)

• Original Article
• Published: 23 October 2017
• S Pradeep1,3,
• M McGuire1,
• S Y Wu1,
• S Ma1,
• H Hatakeyama1,
• Y A Lyons1,
• T Hisamatsu1,
• K Noh1,4,
• A Villar-Prados1,
• X Chen1,
• C Ivan5,6,
• C Rodriguez-Aguayo5,6,
• W Hu1,
• G Lopez-Berestein5,6,
• R L Coleman1 &
• …
• A K Sood1,5

Oncogene volume 37, pages 722–731 (2018)Cite this article

• 1608 Accesses
• 32 Citations
• 14 Altmetric
• Metrics details

Subjects

Abstract

Anti-vascular endothelial growth factor (VEGF) therapy has demonstrated efficacy in treating human metastatic cancers, but therapeutic resistance is a practical limitation and most tumors eventually become unresponsive. To identify microenvironmental factors underlying the resistance of cancer to antiangiogenesis therapy, we conducted genomic analyses of intraperitoneal ovarian tumors in which adaptive resistance to anti-VEGF therapy (B20 antibody) developed. We found that expression of the microseminoprotein, prostate-associated (MSMP) gene was substantially upregulated in resistant compared with control tumors. MSMP secretion from cancer cells was induced by hypoxia, triggering MAPK signaling in endothelial cells to promote tube formation in vitro. Recruitment of the transcriptional repressor CCCTC-binding factor (CTCF) to the MSMP enhancer region was decreased by histone acetylation under hypoxic conditions in cancer cells. MSMP siRNA, delivered in vivo using the DOPC nanoliposomes, restored tumor sensitivity to anti-VEGF therapy. In ovarian cancer patients treated with bevacizumab, serum MSMP concentration increased significantly only in non-responders. These findings imply that MSMP inhibition combined with the use of antiangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 50 print issues and online access

$259.00 per year

only $5.18 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

References

1. Hillen F, Griffioen AW . Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26: 489–502.
   Article PubMed PubMed Central Google Scholar
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth invivo. Nature 1993; 362: 841–844.
   Article CAS PubMed Google Scholar
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–2483.
   Article CAS PubMed Google Scholar
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–2496.
   Article CAS PubMed Google Scholar
5. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302–1308.
   Article CAS PubMed Google Scholar
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
   Article CAS PubMed Google Scholar
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550.
   Article CAS PubMed Google Scholar
8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422–5428.
   Article CAS PubMed PubMed Central Google Scholar
9. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–4740.
   Article CAS PubMed Google Scholar
10. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248–1250.
    Article CAS PubMed Google Scholar
11. Pei X, Sun Q, Zhang Y, Wang P, Peng X, Guo C et al. PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2. J Immunol 2014; 192: 1878–1886.
    Article CAS PubMed Google Scholar
12. Valtonen-Andre C, Bjartell A, Hellsten R, Lilja H, Harkonen P, Lundwall A . A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. Biol Chem 2007; 388: 289–295.
    Article CAS PubMed Google Scholar
13. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015; 43: D670–D681.
    Article CAS PubMed Google Scholar
14. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013; 41: D56–D63.
    Article CAS PubMed Google Scholar
15. Ghirlando R, Felsenfeld G . CTCF: making the right connections. Genes Dev 2016; 30: 881–891.
    Article CAS PubMed PubMed Central Google Scholar
16. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437–443.
    Article PubMed Google Scholar
17. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107: 133–138.
    Article CAS PubMed Google Scholar
18. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 2015; 17: 862–867.
    Article CAS PubMed PubMed Central Google Scholar
19. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 251–258.
    Article CAS PubMed PubMed Central Google Scholar
20. Weth O, Paprotka C, Gunther K, Schulte A, Baierl M, Leers J et al. CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin. Nucleic Acids Res 2014; 42: 11941–11951.
    Article CAS PubMed PubMed Central Google Scholar
21. Bast RC Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC . Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–1337.
    Article PubMed PubMed Central Google Scholar
22. Buick RN, Pullano R, Trent JM . Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668–3676.
    CAS PubMed Google Scholar
23. Landen CN, Kim TJ, Lin YG, Merritt W, Kamat AA, Han L et al. Tumor-selective response to antibody-mediated targeting of alpha(v)beta(3) integrin in ovarian cancer. Neoplasia 2008; 10: 1259–1267.
    Article CAS PubMed PubMed Central Google Scholar
24. Lau DH, Lewis AD, Ehsan MN, Sikic BI . Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991; 51: 5181–5187.
    CAS PubMed Google Scholar
25. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ . Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447–454.
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

SP is supported by a Foundation for Women’s Cancer grant and Ovarian Cancer Research Fund Alliance. SW is supported by Ovarian Cancer Research Fund Alliance, Foundation for Women’s Cancer, Texas Center for Cancer Nanomedicine, and Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489, respectively). KN is supported by the Ovarian Cancer Research Fund Alliance (grant 292015) and KRIBB Research Initiative Program. TH is supported by Uehara Memorial Foundation Research Fellowships for Research Abroad. Portions of this work were supported by the National Institutes of Health grants (CA016672, CA109298, P50 CA083639, P50 CA098258 and UH3 TR000943), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), American Cancer Society Research Professor Award, Blanton-Davis Ovarian Cancer Research Program, RGK Foundation and the Frank McGraw Memorial Chair in Cancer Research.

Author information

Authors and Affiliations

1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
   T Mitamura, S Pradeep, M McGuire, S Y Wu, S Ma, H Hatakeyama, Y A Lyons, T Hisamatsu, K Noh, A Villar-Prados, X Chen, W Hu, R L Coleman & A K Sood
2. Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
   T Mitamura
3. Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
   S Pradeep
4. Gene Therapy Research Unit, Korea Research Institute of Bioscience and Biotechnology, Dajeon, Republic of Korea
   K Noh
5. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
   C Ivan, C Rodriguez-Aguayo, G Lopez-Berestein & A K Sood
6. Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
   C Ivan, C Rodriguez-Aguayo & G Lopez-Berestein

Authors

1. T Mitamura
   You can also search for this author inPubMed Google Scholar
2. S Pradeep
   You can also search for this author inPubMed Google Scholar
3. M McGuire
   You can also search for this author inPubMed Google Scholar
4. S Y Wu
   You can also search for this author inPubMed Google Scholar
5. S Ma
   You can also search for this author inPubMed Google Scholar
6. H Hatakeyama
   You can also search for this author inPubMed Google Scholar
7. Y A Lyons
   You can also search for this author inPubMed Google Scholar
8. T Hisamatsu
   You can also search for this author inPubMed Google Scholar
9. K Noh
   You can also search for this author inPubMed Google Scholar
10. A Villar-Prados
    You can also search for this author inPubMed Google Scholar
11. X Chen
    You can also search for this author inPubMed Google Scholar
12. C Ivan
    You can also search for this author inPubMed Google Scholar
13. C Rodriguez-Aguayo
    You can also search for this author inPubMed Google Scholar
14. W Hu
    You can also search for this author inPubMed Google Scholar
15. G Lopez-Berestein
    You can also search for this author inPubMed Google Scholar
16. R L Coleman
    You can also search for this author inPubMed Google Scholar
17. A K Sood
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toA K Sood.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

About this article

Cite this article

Mitamura, T., Pradeep, S., McGuire, M. et al. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).Oncogene 37, 722–731 (2018). https://doi.org/10.1038/onc.2017.348

Download citation

• Received: 06 November 2016
• Revised: 31 March 2017
• Accepted: 14 June 2017
• Published: 23 October 2017
• Issue Date: 08 February 2018
• DOI: https://doi.org/10.1038/onc.2017.348

This article is cited by